Debt-to-equity in % of Nuvectis Pharma, Inc. from Q3 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nuvectis Pharma, Inc. quarterly Debt-to-equity history and change rate from Q3 2022 to Q3 2025.
  • Nuvectis Pharma, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 56%, a 12% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Nuvectis Pharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 56% +6% +12% 30 Sep 2025
Q2 2025 59% +16% +36% 30 Jun 2025
Q1 2025 56% +20% +54% 31 Mar 2025
Q4 2024 56% +22% +64% 31 Dec 2024
Q3 2024 50% +18% +56% 30 Sep 2024
Q2 2024 43% +15% +51% 30 Jun 2024
Q1 2024 36% +6% +22% 31 Mar 2024
Q4 2023 34% +7% +26% 31 Dec 2023
Q3 2023 32% -4% -11% 30 Sep 2023
Q2 2023 29% 30 Jun 2023
Q1 2023 30% 31 Mar 2023
Q4 2022 27% 31 Dec 2022
Q3 2022 36% 30 Sep 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.